🌟 Pharmidex is thrilled to announce our participation in the GMP Symposium 2024 in Lyon!
October 11, 2024

We’re excited to connect and engage with industry professionals at this important event, sharing insights on pharmaceutical innovation and best practices in Good Manufacturing Practices (GMP).

πŸ“… Event Date: October 16-18, 2024
πŸ“ Location: Lyon, France
πŸ“ Find Us at Booth #2!
Our Head of Business Development,
Martin Barrett, will be at Booth #2 showcasing our range of services. Don’t hesitate to stop by, meet him, and explore how Pharmidex can support your projects with our cutting-edge expertise in drug discovery and development.

Let’s create impactful collaborations and drive the future of healthcare together! πŸ’Šβœ¨

#Pharmidex #GMPSymposium2024 #PharmaceuticalInnovation #Booth2 #Lyon2024 #BusinessDevelopment #HealthcareCollaboration

We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist
July 30, 2025
We’re Hiring! Senior/Principal Scientist–In Vivo Pharmacologist
July 28, 2025
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. πŸ‘©‍πŸ”¬ πŸ‘¨‍πŸ”¬ Welcome to the team, Gabrielle and Mohammed!
BATA Taste Aversion
July 24, 2025
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: βœ… Bitter-tasting APIs βœ… Unpalatable excipients βœ… The success of taste-masking strategies βœ… Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
More Posts